BlueRock Therapeutics
238 Main Street, 3rd Floor
Cambridge
MA
02142
United States
Tel: 1-857-299-7589
Website: https://bluerocktx.com/about/
Email: hr@bluerocktx.com
About BlueRock Therapeutics
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications.
BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.
BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.
Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us on our website to learn about rewarding career opportunities.
Our CEO, Seth Ettenberg, talking about the importance of Community at BlueRock.
51 articles about BlueRock Therapeutics
-
BlueRock Therapeutics to use Rune Labs' clinical trial platform to better characterize Parkinson's disease state in cell therapy trials
3/14/2023
Rune Labs today announced a partnership with BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG.
-
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
3/14/2023
BlueRock Therapeutics LP today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials.
-
BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure
8/24/2022
BioCardia ® , Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock’s cell therapy product candidates for the treatment of heart failure utilizing BioCardia’s minimally invasive biotherapeutic delivery product candidates.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago. -
BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson's Disease
5/31/2022
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent.
-
BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson's Disease
1/18/2022
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson's disease.
-
BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson's Disease
1/6/2022
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson's disease.
-
Ensoma Taps Gene Therapy Leader as First CEO
10/11/2021
After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO. -
BlueRock Therapeutics Announces New Board Chair, New President and CEO
7/26/2021
BlueRock Therapeutics announced today that Emile Nuwaysir , Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021 . Current Chief Scientific Officer Seth Ettenberg , Ph.D., will assume the role of President an CEO.
-
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease
7/19/2021
BlueRock Therapeutics LP announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson's disease (PD).
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
6/8/2021
Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials.
-
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease
6/8/2021
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the dose administration for the first patient in a Phase 1, open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson's disease.
-
ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
6/8/2021
ClearPoint Neuro, Inc. today congratulates BlueRock Therapeutics on the dose administration for the first patient in a Phase 1, open-label study.
-
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease. -
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind. -
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
5/26/2021
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials
-
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
5/17/2021
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder
-
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease
4/7/2021
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease (PD)."
-
BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer
3/3/2020
BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team.